loading
前日終値:
$1.41
開ける:
$1.4
24時間の取引高:
418.42K
Relative Volume:
0.94
時価総額:
$133.76M
収益:
$69.56M
当期純損益:
$-240.05M
株価収益率:
-0.4576
EPS:
-2.95
ネットキャッシュフロー:
$-121.90M
1週間 パフォーマンス:
-16.67%
1か月 パフォーマンス:
-23.30%
6か月 パフォーマンス:
-56.73%
1年 パフォーマンス:
-69.59%
1日の値動き範囲:
Value
$1.32
$1.41
1週間の範囲:
Value
$1.28
$1.665
52週間の値動き範囲:
Value
$1.28
$5.38

Adc Therapeutics Sa Stock (ADCT) Company Profile

Name
名前
Adc Therapeutics Sa
Name
セクター
Healthcare (1165)
Name
電話
41 21 653 02 00
Name
住所
BIOPOLE, EPALINGES
Name
職員
274
Name
Twitter
Name
次回の収益日
2025-03-21
Name
最新のSEC提出書
Name
ADCT's Discussions on Twitter

ADCT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ADCT
Adc Therapeutics Sa
1.35 133.76M 69.56M -240.05M -121.90M -2.95
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-11-08 開始されました Stephens Overweight
2024-05-30 開始されました Cantor Fitzgerald Overweight
2024-03-28 開始されました Guggenheim Buy
2023-08-10 アップグレード JP Morgan Underweight → Neutral
2023-04-24 ダウングレード BofA Securities Neutral → Underperform
2022-12-06 開始されました CapitalOne Overweight
2022-11-09 ダウングレード BofA Securities Buy → Neutral
2022-09-21 開始されました JP Morgan Overweight
2022-09-09 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-11-09 開始されました Wolfe Research Outperform
2021-08-17 再開されました Jefferies Buy
2021-08-09 開始されました RBC Capital Mkts Outperform
2021-06-15 開始されました Cantor Fitzgerald Overweight
2020-12-03 開始されました Stifel Hold
2020-10-29 開始されました H.C. Wainwright Buy
2020-06-09 開始されました BofA/Merrill Buy
2020-06-09 開始されました Cowen Outperform
すべてを表示

Adc Therapeutics Sa (ADCT) 最新ニュース

pulisher
Apr 01, 2025

ADC Therapeutics Strengthens Team with Major Equity Incentive Package - Stock Titan

Apr 01, 2025
pulisher
Apr 01, 2025

ADC Therapeutics (NYSE:ADCT) Price Target Lowered to $7.00 at Guggenheim - MarketBeat

Apr 01, 2025
pulisher
Apr 01, 2025

HC Wainwright Reaffirms Buy Rating for ADC Therapeutics (NYSE:ADCT) - MarketBeat

Apr 01, 2025
pulisher
Apr 01, 2025

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - PR Newswire

Apr 01, 2025
pulisher
Apr 01, 2025

ADC Therapeutics (NYSE:ADCT) Given “Buy” Rating at HC Wainwright - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ... By GuruFocus - Investing.com Canada

Mar 31, 2025
pulisher
Mar 31, 2025

Guggenheim cuts ADC Therapeutics target to $7, keeps Buy rating By Investing.com - Investing.com UK

Mar 31, 2025
pulisher
Mar 29, 2025

ADC Therapeutics (NYSE:ADCT) Announces Quarterly Earnings Results - MarketBeat

Mar 29, 2025
pulisher
Mar 29, 2025

Bank of New York Mellon Corp Buys 9,750 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

ADC Therapeutics SA (NYSE:ADCT) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 29, 2025
pulisher
Mar 28, 2025

Earnings call transcript: ADC Therapeutics Q4 2024 beats EPS, misses revenue - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

ADC Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 28, 2025
pulisher
Mar 27, 2025

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates - MSN

Mar 27, 2025
pulisher
Mar 27, 2025

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update - StreetInsider.com

Mar 27, 2025
pulisher
Mar 27, 2025

ADC Therapeutics targets $600M–$1B in peak ZYNLONTA revenue amid expansion into DLBCL market - MSN

Mar 27, 2025
pulisher
Mar 27, 2025

ADC Therapeutics SA reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

ADC Therapeutics Q4 Net Income USD -30.727 Million - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

ADC Therapeutics reports Q4 results, beats on EPS but misses revenue By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

ADC Therapeutics reports Q4 results, beats on EPS but misses revenue - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

ADC THERAPEUTICS SA -REDH Earnings Results: $ADCT Reports Quarterly Earnings - Nasdaq

Mar 27, 2025
pulisher
Mar 26, 2025

A Preview Of ADC Therapeutics's Earnings - Benzinga

Mar 26, 2025
pulisher
Mar 25, 2025

ADC Therapeutics Announces Abstracts Accepted for Presentation a - GuruFocus

Mar 25, 2025
pulisher
Mar 25, 2025

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 – Company Announcement - Financial Times

Mar 25, 2025
pulisher
Mar 25, 2025

ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025 - Seeking Alpha

Mar 25, 2025
pulisher
Mar 23, 2025

ADC Therapeutics SA (NYSE:ADCT) Shares Bought by Platinum Investment Management Ltd. - MarketBeat

Mar 23, 2025
pulisher
Mar 20, 2025

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025 - BioSpace

Mar 20, 2025
pulisher
Mar 20, 2025

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financ - GuruFocus

Mar 20, 2025
pulisher
Mar 20, 2025

ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA® - Business Wire

Mar 20, 2025
pulisher
Mar 20, 2025

ADC Therapeutics Sets Date for Crucial Year-End 2024 Financial Update - Stock Titan

Mar 20, 2025
pulisher
Mar 17, 2025

Antibody Drug Conjugates Market to Witness Massive Growth - openPR

Mar 17, 2025
pulisher
Mar 12, 2025

WuXi XDC and AbTis collaborate for antibody-drug conjugates - Pharmaceutical Technology

Mar 12, 2025
pulisher
Mar 11, 2025

ADC THERAPEUTICS SA -REDH Earnings Preview: Recent $ADCT Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Boosts Stock Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

Cantor Fitzgerald Reiterates "Overweight" Rating for ADC Therapeutics (NYSE:ADCT) - MarketBeat

Mar 11, 2025
pulisher
Mar 10, 2025

Does This Valuation Of ADC Therapeutics SA (NYSE:ADCT) Imply Investors Are Overpaying? - Simply Wall St

Mar 10, 2025
pulisher
Mar 09, 2025

Cantor Fitzgerald Reiterates “Overweight” Rating for ADC Therapeutics (NYSE:ADCT) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

ADC Therapeutics (ADCT) Projected to Post Earnings on Wednesday - MarketBeat

Mar 08, 2025
pulisher
Mar 06, 2025

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 06, 2025
pulisher
Mar 05, 2025

ADC Therapeutics (ADCT) to Release Earnings on Wednesday - Defense World

Mar 05, 2025
pulisher
Feb 27, 2025

ADC Therapeutics (NYSE:ADCT) Stock Price Expected to Rise, Stephens Analyst Says - MarketBeat

Feb 27, 2025
pulisher
Feb 26, 2025

ADC Therapeutics (NYSE:ADCT) Price Target Raised to $8.00 - Armenian Reporter

Feb 26, 2025
pulisher
Feb 25, 2025

ADCT stock touches 52-week low at $1.42 amid market challenges - MSN

Feb 25, 2025
pulisher
Feb 25, 2025

ADC Therapeutics (NYSE:ADCT) Price Target Raised to $8.00 at Stephens - Defense World

Feb 25, 2025
pulisher
Feb 21, 2025

ADC Therapeutics SA (NYSE:ADCT) Short Interest Update - MarketBeat

Feb 21, 2025
pulisher
Feb 20, 2025

ADC Therapeutics SA (NYSE:ADCT) Sees Large Drop in Short Interest - Defense World

Feb 20, 2025
pulisher
Feb 15, 2025

ADC Therapeutics Appoints Jennifer Herron as Chief Commercial Officer -November 05, 2019 at 06:00 am EST - Marketscreener.com

Feb 15, 2025
pulisher
Feb 14, 2025

SG Americas Securities LLC Increases Stock Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World

Feb 14, 2025
pulisher
Feb 12, 2025

Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26% - Simply Wall St

Feb 12, 2025
pulisher
Feb 11, 2025

Neuroendocrine Tumors Clinical and Non-Clinical Studies, Key - openPR

Feb 11, 2025
pulisher
Feb 11, 2025

Is Adc Therapeutics SA (ADCT) a good investment opportunity? - US Post News

Feb 11, 2025
pulisher
Feb 10, 2025

Investing in Adc Therapeutics SA (ADCT) Is Getting More Attractive - Knox Daily

Feb 10, 2025

Adc Therapeutics Sa (ADCT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
大文字化:     |  ボリューム (24 時間):